Joseph Schwab MD, MS, to Lead Spine-Oncology Program and Center for Surgical Technology and AI Research at Cedars-Sinai

Joseph H. Schwab, MD, MS, an internationally recognized leader in the diagnosis and treatment of complex orthopaedic and spinal oncology conditions, has joined Cedars-Sinai as the new director of Spine Oncology for Orthopaedic Surgery and the director of the Center for Surgical Technology and AI Research.

Joseph Schwab combines extensive experience in translational research and clinical trials with a record of high-quality clinical care. He specializes in the management of benign and malignant bone tumors as well as spinal disorders, including stenoses and myelopathy. His expertise will drive transformative advancements in spine oncology and surgical technology at Cedars-Sinai.

“Dr. Schwab’s visionary leadership and profound impact on orthopaedic surgery make him an invaluable addition to our leadership team,” said Mark Vrahas, MD, chair of Cedars-Sinai Orthopaedics. “His expertise aligns seamlessly with our mission to deliver exceptional patient care and to pioneer new frontiers in orthopaedic medical research.”

Schwab will lead the expansion of the spine oncology program, providing destination expert care for patients with challenging spine disorders. Under his direction, the Center for Surgical Technology and AI Research will foster interdisciplinary surgery discovery as Cedars-Sinai advances the development of innovative AI and predictive algorithmic applications for complex spine and musculoskeletal oncology care.

“I am honored to join Cedars-Sinai and contribute to the advancement of spine oncology and surgical technology,” Schwab said. “Backed by an exceptional team and leading-edge facilities, we are ready to make groundbreaking strides in patient care, research and innovation.”

Schwab comes to Cedars-Sinai from Harvard Medical School, where he served as an associate professor of Orthopaedic Surgery. He also was chief of the Orthopaedic Spine Center, director of Spinal Oncology and co-director of the Stephan L. Harris Center for Chordoma Care at Massachusetts General Hospital. Additionally, he directed the SORG Research Laboratory, the Center for Physical Artificial Intelligence at Mass General and the Mass General Brigham Orthopaedic Registries.

Schwab is joined at Cedars-Sinai by a team of researchers from the SORG Research Laboratory, including mechanical engineer Hamid Ghaednia, PhD, whose research focuses on the development of biomedical devices and wearables using a combination of analytical and machine learning algorithms.

Schwab received his medical degree and a master’s degree in clinical pathology from Chicago Medical School and completed his residency at the Mayo Clinic, followed by fellowships in spine surgery at the Hospital for Special Surgery in New York and the Rizzoli Institute in Bologna, Italy. He also completed a fellowship in orthopaedic oncology at Memorial Sloan Kettering Cancer Center and received a second master’s degree from the Harvard/MIT Clinical Investigator Training Program.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.